Table 2. Correlation between Sp1, PLD1 and clinicopathologic features of PDAC patients.

Factor	Number	Sp1			PLD1
		Negative	Positive	P	Negative	Positive	P
Gender
Male	51	27 (52.9)	24 (47.1)	0.573	31 (60.8)	20 (39.2)	0.949
Female	26	12 (46.2)	14 (53.8)		16 (61.5)	10 (38.5)
Age
> 60	51	27 (52.9)	24 (47.1)	0.573	30 (58.8)	21 (41.2)	0.577
< 60	26	12 (46.2)	14 (53.8)		17 (65.4)	9 (34.6)
T stage
T3	57	29 (50.9)	28 (49.1)	0.946	37 (64.9)	20 (35.1)	0.239
< T2	20	10 (50.0)	10 (50.0)		10 (50.0)	10 (50.0)
N stage
N0	35	20 (57.1)	15 (42.9)	0.298	23 (65.7)	12 (34.3)	0.443
N1	42	19 (45.2)	23 (54.8)		24 (57.1)	18 (42.9)
M stage
M0	73	37 (50.7)	36(49.3)	0.979	44 (60.3)	29 (39.7)	0.951
M1	4	2 (50.0)	2(50.0)		3 (75.0)	1 (25.0)
TMN stage
> II	63	31 (49.2)	32 (50.8)	0.591	39 (61.9)	24 (38.1)	0.741
I	14	8 (57.1)	6 (42.9)		8 (57.1)	6 (42.9)
Primary tumor location
Head and Neck	40	17 (42.5)	23 (57.5)	0.137	23 (42.5)	17 (57.5)	0.508
Body and Tail	37	22 (59.5)	15 (40.5)		24 (64.9)	13 (35.1)
Nerve invasion
Yes	49	24 (49.0)	25 (51.0)	0.698	30 (61.2)	19 (38.8)	0.965
No	28	15 (53.6)	13 (46.4)		17 (60.7)	11 (39.3)
Vascular invasion
Yes	10	1 (10.0)	9 (90.0)	0.007	3 (30.0)	7 (70.0)	0.041
No	67	38 (56.7)	29 (43.3)		44 (65.7)	23 (34.3)
Nuclear grade
III	26	11 (42.3)	15 (57.7)	0.296	13 (50.0)	13 (50.0)	0.156
< II	51	28 (54.9)	23 (45.1)		34 (66.7)	17 (33.3)